NICE approves enfortumab vedotin and pembrolizumab as first-line therapy for metastatic urothelial cancer, highlighting a significant advancement in cancer care.
Enfortumab vedotin (Padvec™; Astellas Pharma and Pfizer) in combination with pembrolizumab (Keytruda®; Merck & Co/Merck Sharp & Dohme) has been approved a a first-line treatment by the National Institute for Health and Care Excellence (NICE) for prescription for unresectable or metastatic urothelial cancer in the United Kingdom (UK).
No takes yet. Share an insight, caveat, or question.
Peter Hofland (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: